Can weight-loss drugs keep your muscles strong? new trial investigates

NCT ID NCT07527195

Recruiting now Disease control Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 1 study looks at how CagriSema, semaglutide, and cagrilintide affect muscle health in 100 adults aged 50-70 with obesity and slightly high blood sugar. Participants will receive one of the drugs or a placebo for up to 15 months. The main goal is to measure how well muscles take up sugar after insulin stimulation.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CagriSema (cagrilintide and semaglutide), cagrilintide, semaglutide
What this could lead to: If successful, this could show that these weight-loss drugs preserve or improve muscle health during weight loss, potentially leading to better treatments for obesity.
What could go wrong: This is an early Phase 1 trial with only 100 participants, so results may not apply to everyone. The study focuses on muscle changes, not long-term weight loss or safety.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Aarhus Universitetshospital, Steno Diabetes Center Aarhus
RECRUITING

Aarhus N, 8200, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.